Cargando…

SELIMETRY—a multicentre I-131 dosimetry trial: a clinical perspective

Treatment options for patients with thyroid cancer that is no longer sensitive to iodine therapy are limited. Those treatments which currently exist are associated with significant toxicity. The SELIMETRY trial (EudraCT No 2015-002269-47) aims to investigate the role of the MEK inhibitor Selumetinib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wadsley, Jonathan, Gregory, Rebecca, Flux, Glenn, Newbold, Kate, Du, Yong, Moss, Laura, Hall, Andrew, Flanagan, Louise, Brown, Sarah R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Institute of Radiology. 2017
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605100/ https://www.ncbi.nlm.nih.gov/pubmed/28291381 http://dx.doi.org/10.1259/bjr.20160637

Ejemplares similares

Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial
por: Brown, Sarah R., et al.
Publicado: (2019)

Recommendations for Multicentre Clinical Trials Involving Dosimetry for Molecular Radiotherapy
por: Taprogge, J., et al.
Publicado: (2021)

EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for (131)I mIBG treatment of neuroendocrine tumours
por: Gear, Jonathan, et al.
Publicado: (2020)

The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer
por: Taprogge, Jan, et al.
Publicado: (2023)

Imaging and dosimetry for radium-223: the potential for personalized treatment
por: Flux, Glenn D
Publicado: (2017)

Dosimetry-based treatment for Graves’ disease
por: Hyer, Steve L., et al.
Publicado: (2018)

Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy
por: Wadsley, Jon, et al.
Publicado: (2023)

Quantification and dosimetry of small volumes including associated uncertainty estimation
por: Carnegie-Peake, Lily, et al.
Publicado: (2022)

Differentiated thyroid cancer patients potentially benefitting from postoperative I-131 therapy: a review of the literature of the past decade
por: Verburg, Frederik A., et al.
Publicado: (2019)

Evaluation of the physical and biological dosimetry methods in iodine-131-treated patients
por: Ozdal, Ayşegül, et al.
Publicado: (2018)

Individualized (131)I-mIBG therapy in the management of refractory and relapsed neuroblastoma
por: George, Sally L., et al.
Publicado: (2016)

Dosimetry during adjuvant (131)I therapy in patients with differentiated thyroid cancer-clinical implications
por: Szumowski, Piotr, et al.
Publicado: (2021)

Opportunities for research in molecular radiotherapy
por: Flux, Glenn D, et al.
Publicado: (2017)

Standard Operating Procedure for Prospective Individualised Dosimetry for ([131])I-rituximab Radioimmunotherapy of Non-Hodgkin's Lymphoma
por: Calais, Phillipe J., et al.
Publicado: (2012)

SPECT/CT-based dosimetry of salivary glands and iodine-avid lesions following (131)I therapy
por: Abuqbeitah, Mohammad, et al.
Publicado: (2023)

PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme?
por: Haug, Alexander R.
Publicado: (2020)

Pre-clinical quantitative imaging and mouse-specific dosimetry for (111)In-labelled radiotracers
por: Denis-Bacelar, Ana M., et al.
Publicado: (2016)

Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force
por: Stokke, Caroline, et al.
Publicado: (2017)

EANM dosimetry committee series on standard operational procedures: a unified methodology for (99m)Tc-MAA pre- and (90)Y peri-therapy dosimetry in liver radioembolization with (90)Y microspheres
por: Chiesa, Carlo, et al.
Publicado: (2021)

SAT510 I-131 Therapy with Dosimetry for Advanced Thyroid Carcinoma: Recombinant TSH vs Thyroid Hormone Withdrawal
por: Awad, Dana, et al.
Publicado: (2023)

Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project
por: Taprogge, Jan, et al.
Publicado: (2023)

Phase I/II trials of (186)Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival
por: Denis-Bacelar, Ana M., et al.
Publicado: (2016)

Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry.
por: Papanastassiou, V., et al.
Publicado: (1993)

SOLLID – a single centre study to develop methods to investigate the effects of low radiation doses within nuclear medicine, to enable multicentre epidemiological investigations
por: Flux, Glenn, et al.
Publicado: (2021)

Considerations when introducing electronic patient-reported outcome data capture in multicentre oncology randomised controlled trials
por: Philipps, Lara, et al.
Publicado: (2022)

Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey
por: Sjögreen Gleisner, Katarina, et al.
Publicado: (2017)

Validation of Monte Carlo (131)I radiopharmaceutical dosimetry workflow using a 3D‐printed anthropomorphic head and neck phantom
por: Adam, David P., et al.
Publicado: (2022)

A Phase 1 Study of (131)I-CLR1404 in Patients with Relapsed or Refractory Advanced Solid Tumors: Dosimetry, Biodistribution, Pharmacokinetics, and Safety
por: Grudzinski, Joseph J., et al.
Publicado: (2014)

Carotid dosimetry after re-irradiation with (131)Cs permanent implant brachytherapy in recurrent, resected head and neck cancer
por: Walsh, Amanda, et al.
Publicado: (2019)

The Australian Clinical Dosimetry Service: a commentary on the first 18 months
por: Williams, Ivan, et al.
Publicado: (2012)

Radiation dosimetry and first therapy results with a (124)I/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
por: Zechmann, Christian M., et al.
Publicado: (2014)

Multicentric validation of radiomics findings: challenges and opportunities
por: Hatt, Mathieu, et al.
Publicado: (2019)

(131)I–Tositumomab in lymphoma
por: Cheung, M.C., et al.
Publicado: (2009)

Radioiodination and Purification of [(131)I]β-CIT and [(131)I]FP-CIT with an Automated Radiosynthesizer
por: Plhak, Elisabeth, et al.
Publicado: (2022)

Setting up a quantitative SPECT imaging network for a European multi-centre dosimetry study of radioiodine treatment for thyroid cancer as part of the MEDIRAD project
por: Taprogge, Jan, et al.
Publicado: (2020)

(131)I-Caerin 1.1 and (131)I-Caerin 1.9 for the treatment of non-small-cell lung cancer
por: Liu, Na, et al.
Publicado: (2022)

French multicentre survey on the use of inotropes after cardiac surgery
por: Bastien, Olivier, et al.
Publicado: (2005)

Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial
por: Dehbi, Hakim-Moulay, et al.
Publicado: (2019)

InChI: a user’s perspective
por: Bachrach, Steven M
Publicado: (2012)

I-124 Imaging and Dosimetry
por: Kuker, Russ, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_h840l2gvf1fe6bm96rqcakb8ih